[Post-Corona Strategy] SK Group's 'Deep Change' Bearing Bio Fruits on Semiconductor Stem

[Asia Economy Reporter Park So-yeon] SK Group is a representative company expected to leap forward in the post-COVID-19 era. This is because the business portfolio that SK Group is nurturing as new growth engines?semiconductors and materials, healthcare, and future mobility?has become the core value chain of newly emerging business trends through the COVID-19 pandemic.

SK Chairman Chey Tae-won emphasizes 'Deep Change,' a fundamental transformation for survival and growth, as the first step in preparing for the future. The 'Deep Change' emphasized by SK means innovation in the business model. SK plans to strengthen its global competitiveness in the memory semiconductor sector through continuous technology and facility investments, especially in the semiconductor and materials fields. It also intends to continue enhancing competitiveness through vertical integration of core semiconductor materials.

SK Hynix expects that the increase in global server demand due to the spread of remote work and the growth of the gaming industry will become new demand sources. Through prior investments, SK has achieved vertical integration in the semiconductor business not only with SK Hynix but also with semiconductor materials companies such as SK Siltron and SK Materials. SK aims to achieve continuous growth through portfolio diversification in the post-COVID-19 era.

SK’s healthcare business, which has recently shown visible results, will continue to focus on entering the global market in areas such as epilepsy and influenza and pneumonia through the development of synthetic new drugs and vaccines. Furthermore, it plans to secure competitiveness in the production of specialty pharmaceuticals.

SK Biopharm recently began sales in the United States of the epilepsy treatment 'Cenobamate' and the sleep disorder treatment 'Solriamfetol.' SK Bioscience is currently accelerating the development of a COVID-19 vaccine. SK Inc. has also been focusing on securing platforms in the antibody new drug development field by investing in venture companies with machine learning technology related to antibody discovery, such as 'Hummingbird Bioscience' and 'Harbor Biomed.'

This content was produced with the assistance of AI translation services.